<DOC>
	<DOCNO>NCT02430298</DOCNO>
	<brief_summary>The study evaluate effect melatonin prevent concurrent radiochemotherapy induce oral mucositis xerostomia improve quality life head neck cancer patient . This randomized , double-blind , placebo control trial conduct head neck cancer patient . Mixed-block randomization use divide eligible patient two group : melatonin 40 mg match placebo . The patient require take study drug 20 mg suspension radiation 20 mg capsule night ( 21.00 pm ) first night radiation continue 7 week . Standard treatment Radiation 2 Gy 5 fraction/week 7 week Cisplatin chemotherapy base regimen accord standard hospital protocol . Study endpoint level mucositis ( CTCAE scale , WHO scale MTS score ) , level xerostomia ( CTCAE scale , VAS ) , QOL ( FACT-H &amp; N ) , pain ( VAS 0-10 ) adverse event frequency .</brief_summary>
	<brief_title>Topical/Oral Melatonin Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>New diagnostic head neck cancer patient need treatment radiation involve oral cavity area . Never receive radiotherapy chemotherapy Karnofsky performance status &gt; 70 % Stopped smoke Able eat swallow medication Written inform consent Melatonin allergy Active oral cavity inflammation scar Pregnancy Creatinine clearance &lt; 30 ml/min Active periodontal disease Steroids pain killer drug use oral cavity pain except NSAIDs thromboembolism prevention Currently use benzydamine mouthwash</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>